These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 22868352

  • 1. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J, Karrasch M, Scheinin NM, Aalto S, Vahlberg T, Någren K, Helin S, Viitanen M, Rinne JO.
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [Abstract] [Full Text] [Related]

  • 2. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group.
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
    Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO.
    Neurology; 2009 Oct 13; 73(15):1186-92. PubMed ID: 19726751
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D.
    J Alzheimers Dis; 2017 Oct 13; 59(2):603-614. PubMed ID: 28671117
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2017 Dec 01; 140(12):3286-3300. PubMed ID: 29053874
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.
    Park SY, Byun BH, Kim BI, Lim SM, Ko IO, Lee KC, Kim KM, Kim YK, Lee JY, Bu SH, Kim JH, Chi DY, Ha JH.
    Medicine (Baltimore); 2020 Apr 01; 99(16):e19620. PubMed ID: 32311931
    [Abstract] [Full Text] [Related]

  • 14. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS, Seo SW, Kim CH, Jeon S, Kim GH, Noh Y, Cho H, Yoon CW, Kim HJ, Jang EY, Lee J, Kim JH, Chin J, Lee JM, Kim JH, Seong JK, Kim CH, Choe YS, Lee KH, Na DL.
    Neurobiol Aging; 2014 Feb 01; 35(2):291-300. PubMed ID: 24080178
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions.
    Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, Sikkes SA, Twisk J, Adriaanse SM, Zwan MD, Boellaard R, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN.
    Neurology; 2014 May 20; 82(20):1768-75. PubMed ID: 24748672
    [Abstract] [Full Text] [Related]

  • 16. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study Group.
    Neurology; 2012 Oct 16; 79(16):1636-44. PubMed ID: 22786606
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF, Banzo I, De Arcocha-Torres M, Quirce R, Martínez-Rodríguez I, Lavado-Pérez C, Bravo-Ferrer Z, Rodríguez-Rodríguez E, Sánchez-Juan P, Carril JM.
    Nucl Med Commun; 2016 Nov 16; 37(11):1189-96. PubMed ID: 27341411
    [Abstract] [Full Text] [Related]

  • 18. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.
    Brain; 2006 Nov 16; 129(Pt 11):2856-66. PubMed ID: 16854944
    [Abstract] [Full Text] [Related]

  • 19. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P, Amariglio R, Hanseeuw B, Johnson KA, McLaren DG, Chhatwal J, Pascual-Leone A, Rentz D, Sperling RA.
    Neuropsychologia; 2017 May 16; 99():343-349. PubMed ID: 28385579
    [Abstract] [Full Text] [Related]

  • 20. Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images.
    Hosokawa C, Ishii K, Kimura Y, Hyodo T, Hosono M, Sakaguchi K, Usami K, Shimamoto K, Yamazoe Y, Murakami T.
    J Nucl Med; 2015 Dec 16; 56(12):1910-5. PubMed ID: 26359262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.